Hydration calculator with GLP-1 dehydration-risk overlay

GLP-1 Water Intake Calculator

Calculate your daily water intake goal based on body weight, activity level, and climate. The calculator adds a hydration buffer for GLP-1 patients because reduced food intake means less food-sourced water, and GI side effects (nausea 44% Wegovy, 29% Zepbound) increase fluid losses.

Your daily water target

Recommended daily water intake
3,464 mL
(117.1 fl oz)
Includes +500 mL GLP-1 ADJUSTMENT
Baseline
2,964 mL
Hourly sip target
217 mL/hr
Glasses per day
14.6 (8 oz)
GLP-1 add
+500 mL
Hydration tip

Sip ~217 mL every hour across your 16 waking hours rather than drinking large amounts at once. Large volumes on GLP-1 medications can worsen nausea. Keep a water bottle visible as a reminder and monitor urine color — pale yellow indicates adequate hydration.

How the calculator works

The formula is simple and every coefficient is sourced from published guidelines.

  • Base water (EFSA 2010, NASEM 2005) [1][2]: body weight (kg) × 33 mL/kg — the midpoint of the widely cited 30-35 mL/kg/day clinical rule.
  • Activity multiplier (ACSM 2007) [5]: sedentary ×1.0, light ×1.1, moderate ×1.2, very active ×1.3 — compensating for sweat losses during exercise.
  • Climate multiplier: temperate ×1.0, hot/humid ×1.15, hot/dry ×1.2 — higher evaporative and insensible losses in heat.
  • GLP-1 adjustment: +500 mL/day for patients on a GLP-1 agonist (compensating for reduced food-sourced water from appetite suppression). An additional +250 mL/day if actively experiencing GI side effects (nausea, vomiting, diarrhea) to replace fluid losses.

Why GLP-1 patients need more water

Approximately 20% of daily water intake normally comes from food (NASEM 2005) [1]. GLP-1 receptor agonists suppress appetite and reduce caloric intake by 20-35%, which proportionally reduces food-sourced water. Additionally:

  • Nausea and vomiting — affects 44% of Wegovy patients and 29% of Zepbound patients per the FDA labels [3][4]. Both cause direct fluid losses.
  • Diarrhea — affects 30% of Wegovy patients and 21% of Zepbound patients [3][4].
  • Delayed gastric emptying — GLP-1 agonists slow stomach emptying, which can make patients feel full with less fluid. Small, frequent sips are better tolerated than large volumes.

Hydration tips for GLP-1 patients

  • Sip small amounts frequently rather than drinking large volumes at once — large gulps on GLP-1 can worsen nausea.
  • Keep a water bottle visible throughout the day as a reminder.
  • Electrolyte supplements may help if you are experiencing significant GI losses — consult your prescriber.
  • Monitor urine color: pale yellow indicates adequate hydration; dark yellow suggests you need more fluids.

Important disclaimer

This calculator is for educational purposes only and does not constitute medical advice. Individual fluid needs vary based on health conditions, medications (especially diuretics), kidney function, and other factors. Patients with heart failure, kidney disease, or conditions requiring fluid restriction should consult their physician before increasing water intake. Every coefficient was verified against published primary sources.

Related tools and research

References

  1. 1.Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. National Academies Press. 2005. https://nap.nationalacademies.org/catalog/10925/dietary-reference-intakes-for-water-potassium-sodium-chloride-and-sulfate
  2. 2.EFSA Panel on Dietetic Products, Nutrition, and Allergies. Scientific Opinion on Dietary reference values for water. EFSA Journal. 2010. https://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2010.1459
  3. 3.Novo Nordisk. Wegovy (semaglutide) injection, for subcutaneous use — Prescribing Information. FDA / Drugs@FDA. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
  4. 4.Eli Lilly and Company. Zepbound (tirzepatide) injection, for subcutaneous use — Prescribing Information. FDA / Drugs@FDA. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215866s000lbl.pdf
  5. 5.Sawka MN, Burke LM, Eichner ER, Maughan RJ, Montain SJ, Stachenfeld NS; American College of Sports Medicine. American College of Sports Medicine position stand. Exercise and fluid replacement. Med Sci Sports Exerc. 2007. PMID: 17277604.